Finder makes money from featured partners, but editorial opinions are our own.

How to buy CRISPR Therapeutics (CRSP) shares in Australia

Learn how to easily invest in CRISPR Therapeutics shares.

Crispr Therapeutics AG is a biotechnology business with stocks listed in the US. CRISPR Therapeutics shares (CRSP) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was US$55.05 – a decrease of 9.26% over the previous week. Here's how to invest if you're based in Australia.

How to buy shares in CRISPR Therapeutics

  1. Compare share trading platforms. To buy shares in a company listed in the US from Australia you'll need to find a trading platform that offers access to US stock markets. Look for a platform with low brokerage and foreign exchange fees.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, which will typically include your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
  3. Search for CRISPR Therapeutics. Find the share by name or ticker symbol: CRSP. Research its history to confirm it's a solid investment that matches your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until CRISPR Therapeutics reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying using consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of US$56.16, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of CRISPR Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of CRISPR Therapeutics. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights.

CRISPR Therapeutics stock price (NASDAQ:CRSP)

Use our graph to track the performance of CRSP stocks over time.

Have CRISPR Therapeutics's shares ever split?

CRISPR Therapeutics's shares were split on a 333333:100 basis on 18 July 2016. So if you had owned 100 shares the day before the split, the next day you would own 333333 shares. This wouldn't directly have changed the overall worth of your CRISPR Therapeutics shares – just the quantity. However, indirectly, the new 100% lower share price could have impacted the market appetite for CRISPR Therapeutics shares which in turn could have impacted CRISPR Therapeutics's share price.

CRISPR Therapeutics shares at a glance

Information last updated 2024-04-17.
52-week rangeUS$37.55 - US$91.1
50-day moving average US$73.3334
200-day moving average US$59.5007
Target priceUS$85.83
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) US$-1.94

CRISPR Therapeutics share growth calculator

US$

Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.

CRISPR Therapeutics price performance over time

Historical closes compared with the last close of $55.05

1 week (2024-04-12) -9.26%
1 month (2024-03-20) -24.53%
3 months (2024-01-19) -11.20%
6 months (2023-10-20) 42.54%
1 year (2023-04-20) 10.34%
2 years (2022-04-20) -4.39%
3 years (2021-04-20) -54.75%
5 years (2019-04-18) 51.82%

Compare trading platforms to buy CRISPR Therapeutics shares

Name Product Standard brokerage for US shares Currency conversion fee Asset class
eToro
Finder AwardExclusive
eToro
US$0
50-150 pips
ASX shares, Global shares, US shares, ETFs
Finder exclusive: Get 12 months of investment tracking app Delta PRO for free when you fund your eToro account (T&Cs apply).
CFD service. Capital at risk.
Join the world's biggest social trading network when you trade stocks, commodities and currencies from the one account.
Moomoo Share Trading
US$0.99
55 pips or 0.0055 AUD/USD
ASX shares, Global shares, US shares, ETFs
Finder exclusive: Get an additional 30 days on top of the regular brokerage-free period for new accounts. T&Cs apply.
Trade shares on the ASX, the US markets and buy ETFs with Moomoo. Plus join a community over 20 million investors.
Spaceship US Investing
US$0
0.70%
US shares, ETFs
Dive into US markets with $0 brokerage, starting with just a $10 investment.
Unlock US stocks and ETFs with minimal entry barriers, offering straightforward, low-cost options for new and seasoned investors.
Tiger Brokers
Exclusive
Tiger Brokers
US$2
37 pips
ASX shares, Global shares, US shares, ETFs
Finder exclusive: 10 no-brokerage US or ASX market trades in the first 180 days + 7% p.a. on uninvested cash with first deposit of any amount, plus US$30 TSLA + US$30 NVDA shares with deposits up to AU$2000. T&Cs apply.
Trade Australian, US and Asian stocks with no minimum deposit on Tiger Broker’s feature-packed platform.
CMC Invest
Finder Award
CMC Invest
US$0
0.60%
ASX shares, Global shares, Options trading, US shares, ETFs
$0 brokerage on US, UK, Canadian and Japanese markets (FX spreads apply).
Trade over 45,000 shares and ETFs from Australia and 15 major global markets. Plus, buy Aussie shares or ETFs for $0 brokerage up to $1,000 (First buy order of each security, each day - excludes margin loan settled trades).
Webull
US$0.25
0.50% (50 pips)
ASX shares, Global shares, Options trading, US shares, ETFs
Sign up & deposit $200 to get $100 of rewards value, or deposit $1,000 to get $200 worth. Up to $5,450 value available. T&Cs apply.
Trade ASX and US stocks and US options, plus gain access to inbuilt news platforms and educational resources. You can also start trading for less with fractional shares.
Saxo Invested
Saxo Invested
US$1
0.25%
ASX shares, Global shares, Options trading, US shares, ETFs
Access 22,000+ stocks on 50+ exchanges worldwide
Low fees for Australian and global share trading, no inactivity fees, low currency conversion fee and optimised for mobile.
loading
The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.

Is it a good time to buy CRISPR Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

CRISPR Therapeutics share price volatility

Over the last 12 months, CRISPR Therapeutics's shares have ranged in value from as little as US$37.55 up to US$91.1. A popular way to gauge a stock's volatility is its "beta".

CRSP.US volatility(beta: 1.74)Avg. volatility(beta: 1.00)LowHigh

Beta measures a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while CRISPR Therapeutics's is 1.743. This would suggest that CRISPR Therapeutics's shares are more volatile than the average for this exchange and represent, relatively speaking, a higher risk (but potentially also market-beating returns).

CRISPR Therapeutics financials

Revenue TTM US$371.2 million
Operating margin TTM 34.58%
Gross profit TTM US$-570,697,000
Return on assets TTM -6.22%
Return on equity TTM -8.17%
Profit margin -41.38%
Book value 23.522
Market capitalisation US$4.9 billion

TTM: trailing 12 months

CRISPR Therapeutics share dividends

We're not expecting CRISPR Therapeutics to pay a dividend over the next 12 months.

CRISPR Therapeutics overview

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease, and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting CD19 and CTX131 targeting CD70 for oncology and autoimmunune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and VCTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

Stocks similar to CRISPR Therapeutics

Frequently asked questions

More guides on Finder

Ask a Question

You are about to post a question on finder.com.au:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com.au is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder only provides general advice and factual information, so consider your own circumstances, or seek advice before you decide to act on our content. By submitting a question, you're accepting our 1. Terms Of Service and 6. Finder Group Privacy & Cookies Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site